Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Sr. VP, GC & Corp. Sec. | November 06, 2020 | November 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date November 06, 2020 · Filed November 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,540.2981 |
Ending reported balance
After 2020-11-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-11-06 · Exercise / conversion · Acquired 9,000 · Balance 16,540.2981 Row 2 · 2020-11-06 · Sale · Disposed 6,342 · Balance 10,198.2981 F1: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $295.88 to $8296.73, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Row 3 · 2020-11-06 · Sale · Disposed 2,658 · Balance 7,540.2981 F2: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $296.91 to $297.70, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.30 · Expires 2025-11-19 | Direct | 0 |
Reported balance
After 2020-11-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-06 · Exercise / conversion · Disposed 7,860 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.30 · Expires 2025-11-19 | Direct | 14,584 |
Reported balance
After 2020-11-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-06 · Exercise / conversion · Disposed 1,140 · Balance 14,584 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $295.88 to $8296.73, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
F2: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $296.91 to $297.70, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2020 Filed Nov 9, 2020 23:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,140 | $0.00 Strike: $62.30 | $0.00 |
DisclosureSEC source: 0001562180-20-006600 · primarydocument.xml · derivative · entry 5 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,584 Underlying: Common Stock · 1,140 shares Expires 2025-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 23:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,860 | $0.00 Strike: $62.30 | $0.00 |
DisclosureSEC source: 0001562180-20-006600 · primarydocument.xml · derivative · entry 4 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,860 shares Expires 2025-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 23:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 2,658 | $297.28 | $790,179.01 |
DisclosureSEC source: 0001562180-20-006600 · primarydocument.xml · nonDerivative · entry 3 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540.2981 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $296.91 to $297.70, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 23:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 6,342 | $296.41 | $1,879,862.03 |
DisclosureSEC source: 0001562180-20-006600 · primarydocument.xml · nonDerivative · entry 2 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,198.2981 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $295.88 to $8296.73, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 23:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 9,000 | $62.30 | $560,700.00 |
DisclosureSEC source: 0001562180-20-006600 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,540.2981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 5, 2020 21:13 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,805 | $189.38 | $341,836.86 |
DisclosureSEC source: 0001562180-20-003387 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540.2981 F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $189.38 to $189.4094, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:10 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 7,652 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001562180-20-001429 · primarydocument.xml · derivative · entry 2 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,652 Underlying: Common Stock · 7,652 shares Expires 2030-02-18 F3 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:10 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,052 | $173.22 | $355,447.44 |
DisclosureSEC source: 0001562180-20-001429 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620.6517 F1 · shares: 2017 PSUs (PP16) award vesting. F2 · balance_after: Balance on form 4 that was filed on November 22, 2019 was incorrectly reported due to the share withholding amount changing. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 12:17 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 2,151 | $149.72 | $322,047.72 |
DisclosureSEC source: 0001562180-19-005718 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,528.6517 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,575 | $106.14 | $273,310.50 |
DisclosureSEC source: 0001562180-19-001640 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 17,926.4554 F1 · shares: Bonus & Incentive share grant Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 12,240 | $102.51 Strike: $102.51 | $1,254,722.40 |
DisclosureSEC source: 0001562180-19-001225 · primarydocument.xml · derivative · entry 2 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,240 Underlying: Common Stock · 12,240 shares Expires 2029-02-19 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 5,120 | $102.51 | $524,851.20 |
DisclosureSEC source: 0001562180-19-001225 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 15,351.4554 F1 · shares: 2016 PSUs (PP15) award vesting. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:44 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 15,036 | $89.64 Strike: $89.64 | $1,347,827.04 |
DisclosureSEC source: 0001562180-18-001153 · primarydocument.xml · derivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,036 Underlying: Common Stock · 15,036 shares Expires 2028-02-20 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/20/2019 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:23 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,828 | $93.00 | $263,004.00 |
DisclosureSEC source: 0001562180-18-001012 · primarydocument.xml · nonDerivative · entry 2 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 10,231.4554 F2 · shares: 2015 PSU (PP14) award vesting Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:23 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,785 | $93.00 | $259,005.00 |
DisclosureSEC source: 0001562180-18-001012 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 7,403.4554 F1 · shares: Bonus & Incentive share grant Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:54 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.4706 | $98.67 | $638.45 |
DisclosureSEC source: 0001562180-18-000148 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,679.6517 Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.4419 | $99.11 | $638.46 |
DisclosureSEC source: 0001562180-17-003745 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,618.4554 Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 20:57 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.4517 | $98.96 | $638.46 |
DisclosureSEC source: 0001562180-17-003648 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,612.0135 Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 23:29 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.3245 | $100.95 | $638.46 |
DisclosureSEC source: 0001562180-17-003505 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,605.5618 Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 21:23 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.8037 | $93.84 | $638.46 |
DisclosureSEC source: 0001562180-17-003317 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,599.2373 Read SEC document |
| October 06, 2017 Filed Oct 11, 2017 19:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.6889 | $95.45 | $638.46 |
DisclosureSEC source: 0001562180-17-003245 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,592.4336 Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 13:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.7058 | $95.21 | $638.46 |
DisclosureSEC source: 0001562180-17-003002 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,585.7447 Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 13:32 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 5.2998 | $91.43 | $484.56 |
DisclosureSEC source: 0001562180-17-002925 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,579.0389 F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 20:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 16,724 | $83.47 Strike: $83.47 | $1,395,952.28 |
DisclosureSEC source: 0001562180-17-000850 · primarydocument.xml · derivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,724 Underlying: Common Stock · 16,724 shares Expires 2027-02-21 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/21/2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:02 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,264 | $86.93 | $109,879.52 |
DisclosureSEC source: 0001562180-17-000738 · primarydocument.xml · nonDerivative · entry 2 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 4,561.6399 F3 · shares: Shares represent the portion of the Performance Share Unit Award granted in 2014 that have vested for period 13. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:02 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 3,253 | $86.93 | $282,783.29 |
DisclosureSEC source: 0001562180-17-000738 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 3,297.6399 F1 · shares: Bonus and incentive shares granted on 02/14/2017. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 19:22 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.2543 | $84.83 | $615.38 |
DisclosureSEC source: 0001562180-17-000067 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 44.6572 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:54 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.2714 | $84.63 | $615.38 |
DisclosureSEC source: 0001562180-16-003841 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 37.4029 Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 16:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.6378 | $80.57 | $615.38 |
DisclosureSEC source: 0001562180-16-003669 · primarydocument.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 30.1315 Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 15:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.6788 | $80.14 | $615.38 |
DisclosureSEC source: 0001225208-16-042015 · doc4.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 22.4937 Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 16:09 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 8.1626 | $75.39 | $615.38 |
DisclosureSEC source: 0001225208-16-041224 · doc4.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 14.8149 Read SEC document |
| October 21, 2016 Filed Oct 24, 2016 14:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 6.6523 | $71.68 | $476.84 |
DisclosureSEC source: 0001225208-16-040698 · doc4.xml · nonDerivative · entry 1 MILLER GEORGE LLOYD · CIK 0001472382 · Sr. VP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 6.6523 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.